Lv1
30 积分 2021-10-11 加入
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
7天前
已完结
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment
2个月前
已完结
Single-cell and spatial transcriptomics reveal mechanisms of radioresistance and immune escape in recurrent nasopharyngeal carcinoma
3个月前
已完结
皖公网安备34019202002308
